Mutual Pharmaceutical Company and United Research Laboratories filed an antitrust suit against Reckitt Benckiser on Friday alleging unfair trade practices in the sale and distribution of Mucinex.
The plaintiffs allege Reckitt wrongfully monopolized the market for Mucinex. Reckitt allegedly deliberately blocked the formation of a competitive market for the manufacture and sale of a generic version of the drug.
The suit alleges that Reckitt has failed to provide ERG to Mutual since October 2013 when another company began selling a generic version of the drug. The plaintiffs are seeking an injunction to prevent Reckitt’s alleged monopolistic practices.
Full Content: The Pennsylvania Record
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI